Copyright
©The Author(s) 2022.
World J Gastroenterol. May 7, 2022; 28(17): 1751-1767
Published online May 7, 2022. doi: 10.3748/wjg.v28.i17.1751
Published online May 7, 2022. doi: 10.3748/wjg.v28.i17.1751
Type 1 | Type 2 | Type 3 | |
Relative frequency (%) | 70-80 | 5-6 | 10-15 |
Gender | F > M | F = M | M > F |
Cell of origin | ECL | ECL | ECL, EC, etc. |
Associated disease | AMAG; Pernicious anemia | MEN1; ZES | None (Sporadic) |
Site of tumors | Fundus and corpus | Fundus and corpus, occasionally antrum | Anywhere |
Size of tumors | < 1 cm | < 2 cm | 2-5 cm |
Number of tumors | Multiple | Multiple | Single |
Plasma gastrin level | High | High | Normal |
Gastric acid output | Low or absent | High | Normal |
Metastatic rate (%) | 2-5 | 10-30 | 50-100 |
Tumor related death (%) | Approximately 0 | < 10 | 25-30 |
- Citation: Yin F, Wu ZH, Lai JP. New insights in diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms. World J Gastroenterol 2022; 28(17): 1751-1767
- URL: https://www.wjgnet.com/1007-9327/full/v28/i17/1751.htm
- DOI: https://dx.doi.org/10.3748/wjg.v28.i17.1751